Population Studies, Precision Medicine & Health Disparities

Enable precision medicine research by supporting deep and longitudinal, molecular endophenotyping of existing and new, at-risk cohorts as well cohorts and/or individuals…

Quantify the exposome in existing and new AD cohorts to gain a more precise measure of environmental exposure factors…

Continue to establish new cohorts that include participants across diverse racial, ethnic and socioeconomic backgrounds…

Develop state-of-the-art protocol for assessing dementia on large nationally representative samples…

Expand existing large scale, open-science molecular profiling efforts

Support the inclusion of measures of AD-related phenotypes and environmental exposures in non-AD cohorts...

Augment current and future human cohorts with more advanced, longitudinal immunological profiling (e.g. Cytof) to enable precision medicine research...

Enable access to electronic health records data and provide support for their integration with clinical and molecular data...

Assess epidemiology and mechanistic pathways of disparities in health burden of AD/ADRD.

Develop a system to monitor the magnitude and trends in health disparities in incidence of AD/ADRD.

Characterize nervous system changes in LBD cohorts that have come to autopsy to identify disease-specific underlying mechanisms to guide biomarker and therapeutic approaches.

Identify novel common and rare genetic variants, epigenetic changes, and environmental influences that impact the risk for and clinical features of LBD.

Understand phenotypic heterogeneity and natural history in FTD.

Encourage crosstalk and interdisciplinary collaboration between TBI and dementia researchers.

Establish infrastructure to study TBI as a risk factor for AD/ADRD.